Transforming ophthalmic care through innovative drug delivery, EyeDura is developing preservative-free sustained release eye drops that address significant patient needs in both anterior and posterior eye conditions
News
EyeDura Therapeutics Partners with SERI to Advance Insulin-Based Topical Therapy for Neurotrophic Keratitis
EyeDura Therapeutics has initiated preclinical efficacy studies in collaboration with the Singapore Eye Research Institute (SERI). The studies will advance the company’s lead insulin-based eye drop treatment for neurotrophic keratitis (NK), a rare, degenerative corneal disease affecting approximately 71,000 patients in the United States.
EYEDURA’S SUSTAINED-RELEASE EYE DROP TECHNOLOGY WINS DOUBLE INDUSTRY HONORS
EyeDura Therapeutics Inc. (www.eyedura.com), a developer of preservative-free sustained release ophthalmic therapies, announced that it received top recognition at two major industry forums among a field of innovative ophthalmic startup companies. EyeDura won The Winning Pitch challenge at SightLine during the American Society of Cataract and Refractive Surgery (ASCRS) conference and earned both the Judge’s Choice and People's Choice awards at the Octane Ophthalmology Technology Forum.